Clene Stock Soars 20% on FDA Path for ALS Drug CNM-Au8

Key Developments

Clene Inc. (NASDAQ:CLNN) shares experienced a significant 20% increase after the company reported a successful meeting with the U.S. Food and Drug Administration (FDA). The discussion centered on an accelerated approval pathway for its amyotrophic lateral sclerosis (ALS) drug candidate, CNM-Au8.

Regulatory Pathway Overview

The FDA indicated that Clene's proposed data might be capable of supporting a New Drug Application (NDA) submission. The agency acknowledged that the neurofilament light (NfL) biomarker could potentially serve as a surrogate endpoint, which is a key requirement for the accelerated approval process under Subpart H.

Market and Company Impact

Following the positive regulatory feedback, Clene announced its plan to submit the NDA for CNM-Au8 in the third quarter of 2026. The company is preparing additional information requested by the FDA to link the reduction in NfL to clinical benefits. A Phase 3 confirmatory study is planned to commence in the first quarter of 2027.

Outlook

This development marks a crucial milestone for Clene and a potential step forward for ALS treatment. Investor attention will now focus on the company's ability to meet the FDA's requirements for the NDA submission and the eventual outcome of the confirmatory trial, which will determine the drug's long-term market viability.

FAQ

Q: What is CNM-Au8?
A: CNM-Au8 is an experimental drug candidate developed by Clene Inc. for the treatment of amyotrophic lateral sclerosis (ALS), which has already received Orphan Drug Designation from the FDA.

Q: What is the accelerated approval pathway?
A: It is an FDA program that allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint reasonably likely to predict clinical benefit.

Source: Investing.com